Core Viewpoint - SKG has launched a new lineup of smart massagers, including the H7 Ultra, G7 Pro Fold, and YS100 Foot Massager, aimed at providing innovative, comfortable, and health-focused solutions for muscle tension relief during the holiday season [1]. Company Overview - SKG has been a leader in personal wellness technology for nearly 20 years, specializing in healthtech devices that are fashionable, affordable, and impactful [3]. - The company has ranked as the top smart massager for the past three years and is Sullivan certified [3]. Product Features H7 Ultra - The H7 Ultra offers deep tissue massage with adjustable intensity levels, targeting muscle knots and stiffness, making it ideal for individuals with "tech-neck" [5]. - It features a design that mimics human hands with 360° kneading covers, providing effective pain relief [6]. - The massager includes three speed levels and three strength levels for customizable intensity [7]. - It automatically shuts off after 15 minutes to prevent over-stimulation [8]. - The ergonomic design is optimized for a 60° angle to fit the neck comfortably [9]. - It incorporates 64 red light beads and a large heating area for deep muscle relaxation and pain relief [10]. - The lightweight design enhances portability, making it a stylish gift option [11]. G7 Pro Fold - The G7 Pro Fold is lighter than the H7 Ultra, weighing just 260g, and is designed for portability [14]. - It can be used in various settings, including the office and while traveling, providing on-the-go pain relief [15]. - The device features a 6kHz mid-frequency pulse and a 7,500 RPM motor for effective deep tissue relief [16]. - It includes 7 red lights for enhanced healing and pain relief in the neck and shoulders [17]. - The massager is made from high-quality PU leather and memory foam, allowing for a comfortable fit and customizable settings via a smartphone app [18]. YS100 Foot Massager - The YS100 is designed for deep tissue relief in the feet, beneficial for individuals with foot pain, diabetes, or high blood pressure [19]. - It offers 360° air compression with three speed and intensity settings, utilizing 12 massage heads for comprehensive foot relief [20]. - The heat setting can reach up to 131°F, enhancing pain relief effectiveness [20]. - The design accommodates feet up to US Men's size 13 and can be used at various angles [20]. - The breathable inner liner is easy to clean, ensuring hygiene with regular use [21].

Core Insights - The UK government has made several fiscal policy changes aimed at supporting the tech sector and encouraging investment in startups and scaleups, which is seen as a positive move for the industry [3][4][10]. Taxation and Incentives - The decision not to introduce a targeted wealth tax is viewed favorably, as it would have negatively impacted private investments, particularly in high-growth startups [1]. - Maintaining R&D tax credits is crucial for SMEs, providing them with the stability needed for future planning [1]. - The widening of Enterprise Management Incentives (EMIs) is a significant development, allowing small businesses to offer share options without National Insurance or income tax liabilities, thus aiding in talent retention [2][10]. - Increasing the caps on the Enterprise Investment Scheme (EIS) is noteworthy, as it will enable promising scaleups to access more capital for growth [2][10]. Government Initiatives - The Chancellor announced plans to enhance the Enterprise Investment Scheme to further encourage investment in UK startups and scaleups [3]. - A £300 million allocation to technology in the NHS aims to strengthen the AI innovation ecosystem, with a focus on translating this investment into tangible benefits for patients [6][7]. - The establishment of an AI Growth Lab and a Sovereign AI Unit is intended to scale national capabilities in AI, with the potential to add £400 billion to the UK economy by 2030 [8]. Industry Perspectives - Founders in the tech sector emphasize the need for the government to act as a customer for startups, particularly in AI, to drive productivity and innovation [5]. - Industry leaders highlight the importance of broader economic stability for the tech ecosystem to reach its full potential, as private investment in UK AI lags significantly behind the US [9]. - The Budget includes initiatives to strengthen the innovation ecosystem, such as entrepreneurship fellowships and the British Business Bank's efforts to attract institutional investment into UK scaleups [11][12]. Research and Development - The UKRI is deploying over £38.6 billion towards government priorities, indicating a significant public investment in the early stages of scientific discovery [13]. - There is a call for greater incentives for private individuals and foundations to support early scientific discovery, as current public funding models place the risk on taxpayers without sharing the rewards [14].

Core Insights - Fourier Health has successfully completed an $8.4 million seed funding round to address the inefficiencies in healthcare caused by fragmented patient records [1][2] - The platform, founded by healthtech entrepreneurs James Lloyd and Christopher Lee, integrates with existing electronic health record systems to create tailored summaries [2][5] Funding and Support - The seed funding round was led by Yosemite, with participation from NextGen Venture Partners, Innospark Ventures, and Tau Ventures [2] - Pre-seed backing was also received from Lasagna, NextGen Venture Partners, Myelin, and Despierta [2] Technology and Impact - Fourier Health's platform automates the review and harmonization of patient information, resulting in a 98% reduction in document validation and saving two to three hours of administrative time per patient [3] - The technology achieves an average document sorting turnaround time of under four minutes, leading to a 5% to 10% increase in evaluation and management revenue opportunities and a 10% to 15% growth in physician capacity [4] Clinical Oversight and AI Integration - The platform incorporates a clinician-in-the-loop review process, ensuring that every AI-generated summary is validated by specialists [5] - This structure allows for continuous improvement of the models and ensures compliance with clinical standards [5]

Core Insights - The healthcare sector has emerged as the best performing S&P 500 sector in October, reversing its previous lagging position [1] - The Health Care Select Sector SPDR ETF (XLV) has gained nearly 4.5% this quarter, while the broader S&P 500 remains largely flat [1] - XLV has attracted approximately $872 million in net new money by October 13, making it one of the top 10 equity ETF asset gatherers this quarter [1] Sector Performance - Prior to October, healthcare had experienced outflows of 6% of its start-of-the-year total assets, indicating a significant shift in investor sentiment [3] - The healthcare sector is characterized as defensive, less vulnerable to cyclical trends, and is currently trading at about a 27% discount to the S&P 500 [3][5] - State Street Investment Management projects XLV's 3-5 year earnings growth at 9.3%, compared to the S&P 500's forecast of 12% [3] Stock-Level Insights - Major healthcare stocks have performed well in October, with Eli Lilly up over 12%, Merck up 8%, Amgen up 7.5%, and Gilead up over 5% [5] - XLV, as the largest healthcare ETF with over $36 billion in assets, serves as a market-cap weighted proxy for the sector [6] Future Outlook - The healthcare sector's unique combination of valuation, growth potential, and defensive characteristics may continue to attract investor interest, especially amid macroeconomic uncertainties [7]

Core Insights - Hims & Hers Health Inc. (NYSE:HIMS) has seen a significant stock price increase of 5.86% to close at $57.97, driven by leadership changes and global expansion initiatives [1][3]. Leadership Changes - CEO Andrew Dudum announced Mike Chi as the new Chief Operating Officer, effective November 2, 2025, replacing Nader Kabbani, who will transition to an advisory role focusing on global initiatives [2][3]. - Chi has been with Hims & Hers since 2021, while Kabbani joined in May 2025 [4]. Strategic Focus - The leadership changes are part of the company's strategy to scale operations and enhance innovation in tech and healthcare sectors [3].

Core Points - Premier Health of America Inc. has announced that its Quebec subsidiaries have been registered as ineligible for public contracts for five years due to concerns raised by the Autorité des marchés publics [1][3] - The Quebec subsidiaries received advance notices in February 2025 and implemented corrective measures to address the issues [2] - The ineligibility affects only public contracts in Quebec and does not impact the company's operations in other jurisdictions or with private entities in Quebec [3] - Public contracts in Quebec accounted for 12% of the company's total revenues for the last quarter ending June 30, 2025, and the company is exploring legal remedies [4] Company Overview - Premier Health is a leading Canadian health tech company providing outsourced healthcare services to governments, corporations, and individuals [5] - The company utilizes its proprietary LiPHe platform to drive digital transformation in healthcare services, aiming to offer faster, cheaper, and more accessible care [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on September 16, 2025 Registration No. 333- FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (State or Other Jurisdiction of (I.R.S. Employer Identification Number) LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. Unit 504, Building 3 Studio City ...

Core Insights - Goldman Sachs' chief investment officer, Darren Cohen, identifies AI, fintech, and healthtech as the top sectors for investment opportunities [5]. Group 1: AI - SaaS businesses are not "dead" and are rapidly integrating AI, which will provide them with a competitive advantage [2]. - The evolution of AI is expected to unlock more value for Goldman Sachs' legacy portfolio [2]. - AI is anticipated to have a transformative effect on trading practices and the broader world [3]. Group 2: Fintech - Alternative investments, including hedge funds, real estate, private equity, and private debt, are poised for digital transformation, which Cohen believes will take about a decade [4]. - The fintech sector is highlighted as a significant opportunity due to its potential for digital evolution [4]. Group 3: Healthtech - Historically, Goldman Sachs has not invested much in healthtech, but there has been a "seismic shift" in how healthcare is adopting innovation since the COVID-19 pandemic [6]. - The complexity and messiness of the healthtech ecosystem make it an attractive investment area [6].

Core Insights - Premier Health of America Inc. has reported its unaudited financial results for the third quarter ended June 30, 2025, showing a decline in revenues and an increase in net loss compared to the same period in 2024 [1][2][10] Financial Performance - Revenues for Q3 2025 were CAD 21.91 million, down from CAD 41.48 million in Q3 2024, representing a decrease of approximately 47% [2] - Gross margin for Q3 2025 was CAD 3.49 million, with a gross margin percentage of 15.9%, slightly up from 15.4% in Q3 2024 [2] - Adjusted EBITDA for Q3 2025 was CAD 22, a significant drop from CAD 367K in Q3 2024 [2][10] - The net loss for Q3 2025 was CAD 3.53 million, an improvement from a net loss of CAD 8.45 million in Q3 2024 [2][10] Operational Challenges - The implementation of Quebec's Bill 10 has negatively impacted the Per Diem segment, which now accounts for about 4% of revenues [3] - The travel nurse and northern communities' services are performing well overall, except for a decline in British Columbia due to centralization efforts by health authorities [4] - The company is reorganizing its Quebec operations, including workforce reductions, to align with cost-saving initiatives disclosed in Q4 2024 [5][6] Strategic Focus - The company is shifting its focus from the Per Diem segment to Travel Nurses and is exploring opportunities in the Home Care sector [6] - Ongoing efforts are being made to enhance cost reduction, debt management, and operational efficiency while pursuing organic growth opportunities [6]

Core Insights - AI-related deal activity in the healthcare sector is thriving despite an overall decline in fundraising, with a 20% decrease in companies not leveraging AI [1][2] - Healthtech is leading AI investment, with AI-related deals doubling over the past 12 months, indicating a strong market trend [2] - China is emerging as a significant player in global biotech, with biopharma licensing deals reaching $3 billion in the first half of 2025, surpassing total spending in 2024 [3] AI Spotlight - Back-office applications are a major focus for AI investment, accounting for 44% of all AI investment in the first half of 2025, aimed at reducing administrative burdens [5] - Half of the funding for diagnostics/tools companies is directed towards those utilizing AI, highlighting the growing importance of AI in this sector [5] Investment by Sector - Healthtech raised a total of $8.2 billion in the first half of 2025, marking the strongest half since H1 2022, with Series B deal sizes reaching $40 million, the highest in five years [5] - In the diagnostics/tools sector, while deal activity has slowed, Series A median pre-money valuations and deal sizes reached five-year highs at $38 million and $14 million, respectively [5] - Medical device investments have remained consistent, totaling between $3 billion and $4 billion every half since 2022, although macroeconomic factors may pose risks [5] Biopharma Insights - Late-stage biopharma companies are favored, with median pre-money valuations for Series C+ at $247 million, compared to $46 million for Series A and $87 million for Series B startups [5]